Overview |
bs-11087R |
LRFN2/SALM1 Polyclonal Antibody |
WB, ELISA, IHC-P, IHC-F, IF(IHC-P), IF(IHC-F), IF(ICC), ICC |
Rat |
Human, Mouse, Dog, Cow, Sheep, Pig, Horse, Chicken, Rabbit |
Specifications |
Unconjugated |
Rabbit |
KLH conjugated synthetic peptide derived from human LRFN2/SALM1 |
401-500/789 |
Polyclonal |
IgG |
1ug/ul |
Purified by Protein A. |
0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles. |
Target |
Cell membrane |
leucine rich repeat and fibronectin type III domain containing 2; RP11-535K1.2; fibronectin type III, immunoglobulin and leucine rich repeat domains 2 antibody FIGLER2; Leucine-rich repeat and fibronectin type-III domain-containing protein 2; LRFN2; LRFN2_HUMAN; SALM1; Synaptic adhesion-like molecule 1. |
LRFN2 is a 789 amino acid single-pass type I membrane protein belonging to the LRFN family. Encoded by a gene that maps to human chromosome 6p21.2, LRFN2 is moderately expressed in brain, spleen and testis. LRFN2 contains one fibronectin type-III domain, one Ig-like (immunoglobulin-like) domain and six LRR (leucine-rich) repeats. LRFN2 promotes neurite outgrowth in hippocampal neurons, enhances cell surface expression of two NMDA receptor subunits, NMDA1 and NMDA?1, and may play a role in redistributing PSD-95 to cell periphery. LRFN2 forms heteromeric complexes with LRFN1, LRFN3, LRFN4 and LRFN5, and is capable of forming homomeric complexes, but not across cell junctions. |
Application Dilution |
WB |
1:300-5000 |
ELISA |
1:500-1000 |
IHC-P |
1:200-400 |
IHC-F |
1:100-500 |
IF(IHC-P) |
1:50-200 |
IF(IHC-F) |
1:50-200 |
IF(ICC) |
1:50-200 |
ICC |
1:100-500 |